The COPE Report 1999
Hitherto, there has been a lack of a coordinated approach by editors of scientific and medical journals to breaches of research and publication ethics. The publication in this issue of the journal of the guidelines on good publication practice developed by the Committee on Publication Ethics (COPE) is therefore most welcome. Consensus has been reached on what constitutes good research and the guidelines on study design, ethical approval, and data analysis are sensible and clear. In any case, all researchers should already follow these principles. For many years, there has been controversy on authorship, and guidance is given on avoidance of conflict over this issue. The duty of all authors to take public responsibility for the content of their paper is rightly emphasised. Conflicts of interest are not confined to the authors of papers, and editors and reviewers must ensure that any relevant conflict of interest is disclosed; again sound guidance is given in the report. Guidelines are also available on peer review and greater transparency by journals of their review, selection, and appeal processes is suggested. Ultimately, this can only benefit authors. Plagiarism and redundant publication are issues with which editors are only too familiar and, in some cases, these unethical practices can be diYcult to identify. Advice to authors on how to avoid possible misconduct is given in the report. Most editors are well aware of their duties, but it is good to see these defined here. The mass media are becoming much more concerned with biomedical research, and the guidelines on media relations are timely.
Unfortunately, breaches of research and publication ethics occur, and there have been several recent, celebrated cases. It is clear that the authors of the report have given much thought to some of the thorny issues surrounding the investigation of suspected breaches, and their guidance to editors is very clear. The mechanism for implementation of the guidelines for dealing with serious misconduct, however, is not entirely clear. For example, there does not appear to be a forum for the author(s) suspected of misconduct to rescind the allegations. With the possible grave consequences of an investigation of this nature, future refinements to the guidelines may be required.
As a former editor of the journal, I would have greatly appreciated access to guidelines such as these when considering diYcult issues, and I feel that all editors should endorse this report.
Committee on Publication Ethics: the COPE Report 1999

Guidelines on good publication practice
Why the guidelines were developed COPE was founded in 1997 to address breaches of research and publication ethics. A voluntary body providing a discussion forum and advice for scientific editors, it aims to find practical ways of dealing with the issues, and to develop good practice.
We thought it essential to attempt to define best practice in the ethics of scientific publishing. These guidelines should be useful for authors, editors, editorial board members, readers, owners of journals, and publishers.
Intellectual honesty should be actively encouraged in all medical and scientific courses of study, and used to inform publication ethics and prevent misconduct. It is with that in mind that these guidelines have been produced.
Details of other guidelines on the ethics of research and published codes of conduct are listed in the Appendix.
How the guidelines were developed
The guidelines were developed from a preliminary version drafted by individual members of the committee, which was then submitted to extensive consultation. They address: study design and ethical approval, data analysis, authorship, conflict of interests, the peer review process, redundant publication, plagiarism, duties of editors, media relations, advertising, and how to deal with misconduct.
What they aim to do
These guidelines are intended to be advisory rather than prescriptive, and to evolve over time. We hope that they will be disseminated widely, endorsed by editors, and refined by those who use them. Action 1 All sources and methods used to obtain and analyse data, including any electronic pre-processing, should be fully disclosed; detailed explanations should be provided for any exclusions. 2 Methods of analysis must be explained in detail, and referenced, if they are not in common use. 3 The post hoc analysis of subgroups is acceptable, as long as this is disclosed. Failure to disclose that the analysis was post hoc is unacceptable. 4 The discussion section of a paper should mention any issues of bias which have been considered, and explain how they have been dealt with in the design and interpretation of the study.
Action
1 The award of authorship should balance intellectual contributions to the conception, design, analysis and writing of the study against the collection of data and other routine work. If there is no task that can reasonably be attributed to a particular individual, then that individual should not be credited with authorship. 2 To avoid disputes over attribution of academic credit, it is helpful to decide early on in the planning of a research project who will be credited as authors, as contributors, and who will be acknowledged. 3 All authors must take public responsibility for the content of their paper. The multidisciplinary nature of much research can make this diYcult, but this can be resolved by the disclosure of individual contributions. 4 Careful reading of the target journal's "Advice to authors" is advised, in the light of current uncertainties.
Conflicts of interest Definition
Conflicts of interest comprise those which may not be fully apparent and which may influence the judgment of author, reviewers, and editors. They have been described as those which, when revealed later, would make a reasonable reader feel misled or deceived.
They may be personal, commercial, political, academic or financial.
"Financial" interests may include employment, research funding, stock or share ownership, payment for lectures or travel, consultancies and company support for staV. Action 1 All sources should be disclosed, and if large amounts of other people's written or illustrative material is to be used, permission must be sought.
Duties of editors Definition
Editors are the stewards of journals. They usually take over their journal from the previous editor(s) and always want to hand over the journal in good shape. Most editors provide direction for the journal and build a strong management team. They must consider and balance the interests of many constituents, including readers, authors, staV, owners, editorial board members, advertisers and the media. Action 1 Editors' decisions to accept or reject a paper for publication should be based only on the paper's importance, originality, and clarity, and the study's relevance to the remit of the journal. 2 Studies that challenge previous work published in the journal should be given an especially sympathetic hearing. 3 Studies reporting negative results should not be excluded. 4 All original studies should be peer reviewed before publication, taking into full account possible bias due to related or conflicting interests. 5 Editors must treat all submitted papers as confidential. 6 When a published paper is subsequently found to contain major flaws, editors must accept responsibility for correcting the record prominently and promptly.
Media relations Definition
Medical research findings are of increasing interest to the print and broadcast media. Journalists may attend scientific meetings at which preliminary research findings are presented, leading to their premature publication in the mass media. journalists are to attend scientific meetings. 6 It may be helpful to authors to be advised of any media policies operated by the journal in which their work is to be published.
Advertising Definition
Many scientific journals and meetings derive significant income from advertising. Reprints may also be lucrative.
Action 1 Editorial decisions must not be influenced by advertising revenue or reprint potential: editorial and advertising administration must be clearly separated. 2 Advertisements that mislead must be refused, and editors must be willing to publish criticisms, according to the same criteria used for material in the rest of the journal. 3 Reprints should be published as they appear in the journal unless a correction is to be added.
Dealing with misconduct 1 Principles
1 The general principle confirming misconduct is intention to cause others to regard as true that which is not true. 2 The examination of misconduct must therefore focus, not only on the particular act or omission, but also on the intention of the researcher, author, editor, reviewer or publisher involved. 3 Deception may be by intention, by reckless disregard of possible consequences, or by negligence. It is implicit, therefore, that "best practice" requires complete honesty, with full disclosure. 4 Codes of practice may raise awareness, but can never be exhaustive.
2 Investigating misconduct 1 Editors should not simply reject papers that raise questions of misconduct. They are ethically obliged to pursue the case. However, knowing how to investigate and respond to possible cases of misconduct is diYcult. 2 COPE is always willing to advise, but for legal reasons, can only advise on anonymised cases. 3 It is for the editor to decide what action to take.
3 Serious misconduct 1 Editors must take all allegations and suspicions of misconduct seriously, but they must recognise that they do not usually have either the legal legitimacy or the means to conduct investigations into serious cases.
2 The editor must decide when to alert the employers of the accused author(s). 3 Some evidence is required, but if employers have a process for investigating accusations-as they are increasingly required to do-then editors do not need to assemble a complete case. Indeed, it may be ethically unsound for editors to do so, because such action usually means consulting experts, so spreading abroad serious questions about the author(s). 4 If editors are presented with convincing evidenceperhaps by reviewers-of serious misconduct, they should immediately pass this on to the employers, notifying the author(s) that they are doing so. 5 If accusations of serious misconduct are not accompanied by convincing evidence, then editors should confidentially seek expert advice. 6 If the experts raise serious questions about the research, then editors should notify the employers. 7 If the experts find no evidence of misconduct, the editorial processes should proceed in the normal way. 8 If presented with convincing evidence of serious misconduct, where there is no employer to whom this can be referred, and the author(s) are registered doctors, cases can be referred to the General Medical Council. 9 If, however, there is no organisation with the legitimacy and the means to conduct an investigation, then the editor may decide that the case is suYciently important to warrant publishing something in the journal. Legal advice will then be essential. 10 If editors are convinced that an employer has not conducted an adequate investigation of a serious accusation, they may feel that publication of a notice in the journal is warranted. Legal advice will be essential. 11 Authors should be given the opportunity to respond to accusations of serious misconduct.
Less serious misconduct
1 Editors may judge that it is not necessary to involve employers in less serious cases of misconduct, such as redundant publication, deception over authorship, or failure to declare conflict of interest. Sometimes the evidence may speak for itself, although it may be wise to appoint an independent expert. 2 Editors should remember that accusations of even minor misconduct may have serious implications for the author(s), and it may then be necessary to ask the employers to investigate. 3 Authors should be given the opportunity to respond to any charge of minor misconduct. 4 If convinced of wrongdoing, editors may wish to adopt some of the sanctions outlined below.
Sanctions
Sanctions may be applied separately or combined. The following are ranked in approximate order of severity: 1 A letter of explanation (and education) to the authors, where there appears to be a genuine misunderstanding of principles. 2 A letter of reprimand and warning as to future conduct. 3 A formal letter to the relevant head of institution or funding body. 4 Publication of a notice of redundant publication or plagiarism. 5 An editorial giving full details of the misconduct. 6 Refusal to accept future submissions from the individual, unit, or institution responsible for the misconduct, for a stated period. 7 Formal withdrawal or retraction of the paper from the scientific literature, informing other editors and the indexing authorities. Clinical trials and compensation guidelines, January 1991.
Guidelines for phase IV clinical trials, September 1993.
Guidelines on the conduct of investigator site audits, January 1994.
Relationship between the medical profession and the pharmaceutical industry, June 1994.
Good clinical trial practice, November 1995.
Patient information and consents for clinical trials, May 1997.
Guidelines on the structure of a formal agreement to conduct sponsored clinical research, July1998.
Good clinical research practice, July 1998. A 30 year old married man presented with erythematous papules and plaques of 2 months' duration covered with hard limpetlike scales on face, body, and both extremities (fig 1) . Palms and soles showed keratoderma blenorrhagicum and subungual hyperkeratosis with distal onycholysis. Both knees and wrists had painful swelling with restriction of movements. With this clinical presentation Reiter's syndrome was inferred. All routine investigations were normal except a raised erythrocyte sedimentation rate of 100 mm in the first hour. x Rays of the aVected joints were normal. ELISA for HIV-1 and HIV-2 was positive with two kits (Immunocomb, Tri-dot) and confirmed with western blotting technique (Speciality Ranbaxy Limited). The absolute helper T lymphocyte count was 435 cells ×10 6 /l. Human leucocyte antigen B27 and rheumatoid factor were negative. The patient was commenced on prednisolone by mouth 60 mg daily and indomethacin by mouth 25 mg three times daily without any concomitant antiretroviral therapy. New erythematous papules and plaques appeared with no relief in joint pain and swelling.
Council for International Organisations of Medical Sciences (CIOMS). International Guidelines for Ethical
In seeking an eVective treatment, we serendipitously came across the eYcacy of carbamazepine in an HIV infected patient with psoriatic erythroderma. 3 We started carbamazepine 200 mg daily in two divided doses in addition to above. The erythema cleared rapidly within 7 days. To confirm the eVect of carbamazepine, it was stopped. New lesions similar to the old ones appeared within 3-4 days. Carbamazepine was then reintroduced in the same dose. Erythema cleared again within 7 days followed by scaling and joint swelling and pain. New lesions stopped appearing. Prednisolone was then tapered oV rapidly and analgesics were stopped. Carbamazepine was continued in the same dose for 6 months. On follow up at 1 year, the patient showed no recurrence of skin lesions and synovitis, no change in liver and renal function tests, with no further deterioration in his overall health and no opportunistic infections.
It has been proposed that in genetically predisposed people, the release of neuropeptides like substance P, calcitonin gene related peptide, vasoactive intestinal peptide, and the inflammatory leucotriene B4 from cutaneous sensory nerves causes local inflammatory responses that trigger psoriasis.
4 Stimulated mast cells secrete a number of proinflammatory cytokines and proteases that act similarly.
5
Carbamazepine significantly inhibits the uptake of noradrenaline (norepinephrine) and blocks a cyclic AMP mediated calcium influx that is associated with neuropeptide release and control of a slow potassium current.
6
The rapid clearing of erythema, secondary to raised levels of neuropeptides, with carbamazepine may have been mediated through inhibition of these neuropeptides and by inhibition of uptake of noradrenaline. The exacerbation and subsequent resolution of lesions on withdrawal and reinstitution of carbamazepine respectively proves its eYcacy in our patient. Also, the clinical remission maintained for 1 year after stopping carbamazepine confirms its therapeutic role in Reiter's syndrome. The therapeutic response seen in our patient conforms to that seen in the HIV-1 positive patient of Smith et al. 3 This apparent success adds carbamazepine to the armamentarium against Reiter's syndrome in an HIV infected patient. This is the first reported case and an evaluation of long term carbamazepine therapy is warranted. 
Condoms and warts
EDITOR,-Wen et al 1 should be applauded for their attempt to address the key question of whether or not condoms protect people from genital warts. However, some of the major study variables need clarifying, as they did not match up with my knowledge of the Sydney Sexual Health Centre (SSHC) database.
The article discussed the issue of "acquisition of genital warts" and was presented as an incidence study. Cases were defined as: "All patients with a new diagnosis of macroscopic genital warts who attended SSHC [in] 1996." However, many of these patients had been previously diagnosed with genital warts elsewhere while others had recurrent lesions. In Australia, most genital warts are managed by general practitioners. 2 Consequently, the experience of specialist services is biased towards recurrent and diYcult cases. "New diagnosis" in this situation means new to the clinic but not necessarily new to the patient. This means that the main outcome measure was a mixture of incident, prevalent, and recurrent cases, with the possibility that the warts may have aVected the behaviour of many of the study subjects.
The SSHC database does document whether a person has previously been diagnosed with HPV infection. To me, the study would have had more validity if patients with a past history had been excluded.
The diagnostic grouping for warts at SSHC does not distinguish between genital and anal lesions. The readers of the journal need to know that many of these male "genital wart" cases would have been homosexually active men with anal warts. This is important as risk factors for penile and anal warts may diVer, potentially confusing the results of the present study.
Originally developed as an HIV risk measure, the condom use variable at SSHC only refers to the previous 3 months or since the last registration/disease episode. Wen et al's article 1 failed to mention that this variable was time limited. As 3 months is the median duration before the appearance of exophytic warts, 3 up to half of the relevant sexual behaviour may have been overlooked.
Finally, the referent group in the table describing condom use deemed as "Not applicable, no sex" should have been more accurately described as "No vaginal or anal sex in the previous 3 months." Many of these people would have practised oral sex or other sexual acts during those 3 months. Others may have ceased practising vaginal or anal intercourse up to 3 months earlier because of their persistent or recurrent warts.
Large relational quality assured clinical databases can be powerful tools for health service evaluation, surveillance, and the generation of research questions. It may be prudent for researchers to engage the people responsible for designing and maintaining those databases to minimise errors of interpretation. Reply EDITOR,-We are grateful to Dr Dayan for her helpful and constructive comments. The major criticism of our paper relates to the selection of cases, and the possible inclusion of prevalent and recurrent cases as well incident cases. However, our concern with this possible bias at the outset of the study led us to exclude all patients with a history of previous genital warts. This included those previously diagnosed at SSHC, and those who gave a history of having their warts managed elsewhere. Consequently, when we state a new diagnosis of genital warts, this is precisely what we mean. With regard to the conduct of the study, this was performed with the assistance of the current data manager responsible for the SSHC data base, whose help and assistance were duly acknowledged. ADRIAN 
LINDA DAYAN
Photosensitivity reaction to efavirenz
EDITOR,-The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is a recent addition to the armamentarium available to physicians in the treatment of HIV infection. However, at present the known side eVect profile of this new agent is still in its infancy. We would like to report a case of photosensitivity associated with efavirenz.
A 27 year old white homosexual man was commenced on combivir (zidovudine/ lamivudine) and efavirenz in March of 1999. One month later he reported that he was well and had no major side eVects associated with his new combination. However, 4 weeks further into treatment he represented with an itchy rash aVecting his arms and hands. On examination there was a maculopapular rash over the aVected area but there was no oral ulceration, conjunctivitis, or fever. A drug reaction was diagnosed and he was prescribed antihistamines and asked to continue with his medication. One week later the rash had subsided. Then having spent a day outside in the sun he had a florid recurrence of the rash over the exposed areas (arms, back of neck, face, and ears). The rash was significantly worse over his elbows where there was obvious blistering and oedema. His medication was stopped and 3 weeks later the rash had completely resolved. Hepatitis C antibody and porphyria screening were negative. This man had been diagnosed as HIV antibody positive in June 1997. In March 1998 his viral load was 356 790 copies/ml (Roche PCR) and his CD 4 count was 512 × 10 6 cells/l, he was commenced on dual antiretroviral therapy with stavudine and didanosine (patient choice). Initially he did very well as the viral load became undetectable (<400 copies/ml). However, after 9 months on this combination his viral load began to rebound (5192 copies/ml) and a change in antiretroviral therapy was initiated to combivir and nevirapine which he initiated in the normal way (dose escalation at 2 weeks of nevirapine). He was started on this combination as he wished to take a protease sparing regimen. However, 1 week later he developed a rash aVecting his entire body, especially his trunk and arms, associated with enlarged lymph nodes and constitutional symptoms, fever, and lethargy. In view of the constitutional symptoms it was decided to stop this present combination. One month later, the rash had settled, he then commenced combivir and efavirenz.
Photosensitivity in the context of HIV has been reported as a presenting sign of underlying HIV infection in a number of cases.
1-3 In addition to this porphyria cutanea tarda (PCT) has been reported in the context of HIV infection and has been associated with concomitant hepatitis C infection 4 ; however, screening for both these conditions was negative. Switching from nevirapine to efavirenz in this context may have been regarded as unwise; however, of 19 patients who have been intolerant of nevirapine secondary to the development of rash, who have switched to efavirenz only nine have developed a mild to moderate rash, of which only two needed to discontinue therapy.
5 Photosensitivity in the context of HIV infection may not only be a presenting condition but also secondary to concomitant treatment. We conducted a retrospective review of all HIV infected patients diagnosed with CMV retinitis at Fairfield Hospital and the Alfred Hospital between 1984 and 1996, aiming to identify factors at diagnosis of CMV retinitis which were predictive of outcome. Both hospitals had the same protocol for the treatment of CMV retinitis and employed 3 monthly ophthalmological screening of all HIV infected patients with CD4 counts of less than 50 ×10 6 /l. The study outcomes were visual loss and death. Moderate visual loss was defined as a visual acuity of less than 6/12 in the better eye, and severe visual loss as visual acuity of less than 6/60 in the better eye (this is legal blindness in Australia).
CMV retinitis was diagnosed in 212 of 1281 patients (16.5%) with AIDS over the study period. As of June 1998, 193 (93%) had died, at a median time of 36 weeks (range 0-192) from CMV diagnosis. Seventy four patients (35%) developed moderate visual loss at a median time of 23 weeks (range 0-163) and 30 patients (14%) developed severe visual loss at a median time of 35 weeks (range 0-120) from diagnosis of CMV retinitis.
The presence of visual symptoms at diagnosis of CMV retinitis was predictive of the development of moderate visual loss (relative risk 2.1, 95% confidence interval 1.1-4.2). Fifty eight of 138 patients (42%) with visual symptoms at diagnosis developed moderate visual loss, compared with 16 of 64 patients (25%) who were asymptomatic at diagnosis (p=0.02). The presence of visual symptoms at diagnosis was not predictive of the development of severe visual loss, or early death (p>0.2). Other factors measured at diagnosis of CMV retinitis included the patients' age, CD4 count, weight, visual acuity, and the presence of any previous AIDS defining condition. None of these was associated with the development of visual loss or early death (p>0.1).
The advent of highly active antiretroviral therapy (HAART) has resulted in a reduction in the incidence of new diagnoses of opportunistic infections. Prolonged survival times with CMV retinitis have been demonstrated in patients who achieve immunological recovery with HAART.
1 2 The ability to predict those patients who are at highest risk of visual loss may assist in advising those who may reasonably cease maintenance therapy for CMV retinitis following immune restoration. An understanding of the natural history of CMV retinitis in the pre-HAART years remains important in managing patients who are failing HIV therapy.
The only factor measurable at diagnosis of CMV retinitis that was predictive of outcome was the presence of visual symptoms. The use of routine ophthalmological screening in HIV infected individuals with low CD4 counts aims to detect CMV retinitis before visual symptoms occur. It is possible that visual loss may be prevented by detecting disease before retinal damage occurs. A prospective evaluation is needed to confirm this finding.
Azithromycin v oxytetracycline for the treatment of non-specific urethritis EDITOR,-Single dose azithromycin 1 g rather than multidose tetracyclines or erythromycin over several days for the treatment of chlamydial infections is becoming more widespread as patient acceptability and improved compliance outweigh cost considerations. However, in men, treatment is often initiated on the basis of microscopic evidence of urethritis before the chlamydial result is available. Relatively few studies report the eYcacy of azithromycin in the treatment of nongonococcal non-chlamydial urethritis (NSU), 1-3 but recently published evidence based guidelines for the management of NSU recommend either doxycycline 100 mg twice daily for 7 days or azithromycin 1 g immediately. 4 In this genitourinary medicine clinic azithromycin became first line treatment for all proved or suspected chlamydial infections from 1 April 1998. This retrospective study assessed the eYcacy of azithromycin for the treatment of NSU compared with oxytetracycline 250 mg four times daily for 7 days, the previous first line treatment regimen for men with microscopic urethritis in whom no Gram negative diplococci were evident.
The outcome of all men with NSU diagnosed between 1 April 1998 and 30 September 1998 (treated with azithromycin) was compared with those diagnosed between 1 April 1997 and 30 September 1997 (treated with oxytetracycline).
NSU was defined as the presence of at least five polymorphonuclear leucocytes (PMNL) in five or more fields on microscopy of a urethral smear, negative culture of Neisseria gonorrhoea after direct plating onto modified New York culture medium and negative chlamydial screen on ELISA testing (Syva) of a urethral swab.
"Cure" was defined as either resolution of symptoms or clearing of previously positive two glass urine. A repeat urethral smear was not examined routinely.
"Treatment failure" was defined as persistent PMNL on microscopy of a urethral smear taken because of ongoing symptoms or persistent positive two glass urine test, with possibility of reinfection denied.
The results (see table 1) demonstrate that azithromycin is as eVective as oxytetracycline in curing NSU, and produces fewer treatment failures, possibly owing to better compliance with single dose therapy. Compliance with multidose regimens might be expected to be less good in asymptomatic patients, but with no satisfactory "test of cure" this was diYcult to ascertain. Overall, there was a 25% non-attendance rate for follow up, biased towards the asymptomatic patients and those treated with oxytetracycline.
The results of the two glass urine test did not diVer significantly between the two groups but overall was positive in 70% of symptomatic patients compared with only 47% asymptomatic (p<0.01) Its low sensitivity and specificity 4 are likely to be even lower in asymptomatic patients. Default from follow up occurred more frequently in the asymptomatic patients, but was less evident in the azithromycin treated group, who had a lower default rate overall, as previously reported.
5
In conclusion, although the numbers are small, it would appear that azithromycin is an eVective treatment for NSU, and can be given at the time of initial diagnosis, pending the chlamydial result. Financial considerations preclude the use of azithromycin as first line treatment for NSU in many centres, but better compliance resulting in fewer treatment failures, and fewer wasted appointments from defaults may counter the economic argument. We, in our genitourinary medicine department at Royal Berkshire Hospital, Reading, studied the reasons for attendance of elderly people and compared them with the younger age group. Data were collected from patients aged 60 and above who attended the clinic between January 1998 and December 1998. Randomly selected sex matched people aged 20-35 years are taken for comparison.
A total of 68 elderly people attended the clinic. The mean age was 66.5 years (range 60-83); 61 (90%) were male and seven (10%) were female. Forty one (60%) attended for STI screening and 27 (40%) attended for non-STI management. In the younger age group 60 (88%) attended for STI screening and eight (12%) attended for non-STI management (p<0.001). Sixteen (24%) older attendees had an STI compared with 35 (51%) in the younger age group (see table 1). Of the 16 older attendees with suspected STIs 11(68%) waited over 2 weeks between symptom recognition and clinic attendance. Of 31 symptomatic attendees in the younger age group 10 (32%) waited over 2 weeks for symptom recognition and clinic attendance (p <0.001).
Many elderly people maintain heterosexual and homosexual activity. Therefore this age group is at a risk of all sexually transmitted infections.
2
In our study, a smaller percentage of older attendees had STIs compared with previous studies. However, the number of older patients who attended for non-STI management are comparable. The delay between symptom recognition and healthcare presentation is a feature of STI related illness behaviour. The delay behaviour among individuals with suspected STIs is age specific, with longer latency periods experienced by people over the age of 50. 4 This finding was seen in our study as well. Tertiary syphilis EDITOR,-I read Dr Reed's letter on tertiary syphilis 1 with interest. The regimen he describes for the treatment of early syphilis-arsenic, bismuth, and round the clock aqueous penicillin, was used in our hospital from 1946-8 2 although daily penicillin in beeswax was also used. It was unclear how much inactive penicillin K was in the commercial product used. The penicillin regimen used here was higher than in Lincoln (40 000-75 000 units 3-4 hourly). There were 10 treatment failures (?reinfections) out of 275 patients described. The most striking first impression of these two volumes is the lavish production with marvellous illustrations, photographs, and tables. It has many excellent features. The text is well set out and easy on the eye. The experience of the authors in approaching various diseases and clinical syndromes comes through strongly. The sections comprehensively cover infectious disease from basic science to clinical management. The clinical microbiology section is an important anchor and could be a short textbook in itself. I very much enjoyed the numerous practice points, which are oriented towards clinicians faced with funding solutions to problems. These consist of short essays with tables or illustrations and tackle particular clinical problems such as "the diagnosis of HIV in newborns," "what is the treatment of a positive toxoplasma titre in pregnancy?" or are in a debating style-for example, "how long should osteomyelitis be treated?" Each section is colour coded and although the American numbering system takes a few minutes to get used to one can easily navigate around the book. The contributors are all internationally famous in their fields and, with so many of them, I am quite impressed by how up to date the book is. They must have been chased hard to get their contribution in on time. One of the few criticism would be that there could have been more on hepatitis C and its interaction with HIV.
However, if you can't find what you want in this book, there is a comprehensive list of websites, which are of interest to infectious disease and other physicians. There is a free CD ROM which creates a direct internet link to these sites. The other important resource is a slide library, which comes on the same CD ROM. In all, 1500 tables and clinical and other photographs are stored and can be made up into personalised presentations; these can then be used as a teaching resource via computer generated images. The high quality of these images will impress anyone involved in producing material for teaching. However, it is a shame some of the useful tables have not made it from the text to the CD ROM.
Although this book is expensive, I would recommend it to anyone interested in infectious diseases especially those who have to teach at any level, undergraduate or postgraduate.
With the rise of the internet the big textbook might soon be heading for extinction. Thankfully this book delays the time when I will be downloading information from the super highway rather than turning over the pages of a well produced book. I was delighted when the editor sent me this book and asked me to review it. I had looked forward with anticipation to the original series that were published in the BMJ. I had thought then that each article was just superb and now they are all neatly packed together in this ABC, I am of the opinion that this is an excellent book which achieves its aim completely. On the cover, it says "it is an ideal reference for doctors, nurses, students and all those not involved in the area of sexual health," and Professor Adler adds in the foreword that this book will put the profession in touch with the real world, real people, with real problems, and fill a large gap in our knowledge. John Tomlinson, the editor, has pulled together an excellent group of experts who have practical experience in the field and have managed to condense that experience into a series of short articles, all of which make informative, yet entertaining reading. In my opinion, no specific background is required to gain information from these articles and I have recommended specific sections of this book for individual patients who need to read about their problem.
Those of us who work in sexual medicine were amused that the BMJ had to carry a warning about the sexually explicit material inside and, indeed, John Tomlinson refers to this in the preface and admits that a very small number of readers were oVended. However, given the general reticence in society about sexual matters, this is not surprising.
Sexual health is an essential part of having a happy and fulfilling life, and everyone who works in a caring profession should be comfortable when the conversation drifts into areas of sexuality. Patients, who often broach the topic with trepidation, need to be assured of a sensitive hearing. In my opinion, this excellent book will give anyone in the caring profession a good grounding in sexual matters, so that they can explore these areas with patients when appropriate, without embarrassment and have some idea of likely strategies of management. CURRENT
